FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-02								

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Al-Wakeel Yasir B.</u>			<u>N</u>	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [ MACK ]					NC Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201			0.	3. Date of Earliest Transaction (Month/Day/Year) 02/08/2016						A below) below) CFO and Head of Corp Dev					
(Street) CAMBR (City)		ЛА State)	02139 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line	) <mark>X</mark> Form fil	Form filed by More than One Reporting				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date				Transaction te	on	2A. Deem	ed	3. Transacti	4. Secur	ities Acquir		5. Amoun	s Fo	rm: Direct	7. Nature of ndirect
(r			(Me	onth/Day/	Day/Year) if any (Month/Day/		ay/Yeaı	r) 8) `	. (A) or		r Price	Beneficia Owned Fo Reported Transacti (Instr. 3 a	ollowing (i) (	Instr. 4) C	eneficial Ownership nstr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion Date Execution r Exercise (Month/Day/Year) if any rice of erivative		Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$5.42	02/08/2016		A		105,000		(1)	02/07/2026	Common Stock	105,000	\$0.00	105,000	D	

## Explanation of Responses:

1. This option vests as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.

## Remarks:

/s/ Jeffrey A. Munsie, attorney-

02/10/2016

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.